Global Antibody Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2017
No. of pages: 850
Inquire Before Buying

The Global Antibody Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Antibodies

Antibody-drug conjugates

Monoclonal antibodies

Murine mAb

Chimeric mAb

Humanized mAb

Human aAb

Polyclonal Antibodies

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,200 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.

Key benefits

Global Antibody Partnering Terms and Agreements 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Antibody deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Antibody agreements with real life case studies

Detailed access to actual Antibody contracts enter into by the leading fifty bigpharma companies

Insight into the terms included in a Antibody agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Antibody Partnering Terms and Agreements 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.

Global Antibody Partnering Terms and Agreements 2010 to 2017 includes:

Trends in Antibody dealmaking in the biopharma industry since 2010

Analysis of Antibody deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Antibody deals

Access to over 1,200 Antibody online deal records

The leading Antibody deals by value since 2010

Most active Antibody dealmakers since 2010

The leading Antibody partnering resources

In Global Antibody Partnering Terms and Agreements 2010 to 2017, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Antibody Partnering Terms and Agreements 2010 to 2017 report provides comprehensive access to available deals and contract documents for over 1,200 Antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise Antibody rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Antibody Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking
2.1. Introduction
2.2. Antibody partnering over the years
2.3. Most active antibody dealmakers
2.4. Antibody partnering by deal type
2.5. Antibody partnering by therapy area
2.6. Deal terms for antibody partnering
2.6.1 Antibody partnering headline values
2.6.2 Antibody deal upfront payments
2.6.3 Antibody deal milestone payments
2.6.4 Antibody royalty rates

Chapter 3 - Leading antibody deals
3.1. Introduction
3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers
4.1. Introduction
4.2. Most active antibody dealmakers
4.3. Most active antibody partnering company profiles

Chapter 5 - Antibody contracts dealmaking directory
5.1. Introduction
5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Antibody deals by company A-Z

Appendix 2 - Antibody deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Antibody deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

Appendix 4 - Antibody deals by therapy area

Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Respiratory

Appendix 5 -Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Therapeutic antibody definitions
Figure 2: Antibody partnering since 2010
Figure 3: Active antibody dealmaking activity since 2010
Figure 4: Antibody partnering by deal type since 2010
Figure 5: Antibody partnering by disease type since 2010
Figure 6: Antibody deals with a headline value
Figure 7: Antibody deals with an upfront value
Figure 8: Antibody deals with a milestone value
Figure 9: Antibody deals with a royalty rate value
Figure 10: Top antibody deals by value since 2010
Figure 11: Most active antibody dealmakers since 2010
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events
  • United States Monoclonal Mouse Antibody Market by Manufacturers, States, Type and Application, Forecast to 2023
    Published: 06-Apr-2018        Price: US 4480 Onwards        Pages: 103
    Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called "antigens"). The technology behind the generation of monoclonal antibodies was discovered in 1972 by César Milstein and Georges Kohler - scientists at the Roche-funded Basel Institute for Immunology - who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological researc......
  • Antibody Market Report by Company, Regions, Types and Applications, Global Status and Forecast to 2025
    Published: 02-Apr-2018        Price: US 4250 Onwards        Pages: 154
    Summary This report studies the Antibody market status and outlook of global, from angles of players, regions, product types and end industries; this report analyzes the top players in global market, and splits the Antibody market by product type and application/end industries. The global Antibody market was XX million US$ in 2017 and is expected to XX million US$ by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this......
  • 2018-2025 Antibody Report on Global and United States Market, Status and Forecast, by Players, Types and Applications
    Published: 18-Mar-2018        Price: US 3600 Onwards        Pages: 122
    Summary This report studies the Antibody market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Antibody market by product type and application/end industries. The global Antibody market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between......
  • Asia-Pacific Monoclonal Mouse Antibody Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Mar-2018        Price: US 4480 Onwards        Pages: 103
    Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called "antigens"). The technology behind the generation of monoclonal antibodies was discovered in 1972 by César Milstein and Georges Kohler - scientists at the Roche-funded Basel Institute for Immunology - who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological researc......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Monoclonal Mouse Antibody Market 2018 Forecast to 2023
    Published: 02-Mar-2018        Price: US 4880 Onwards        Pages: 103
    Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called "antigens"). The technology behind the generation of monoclonal antibodies was discovered in 1972 by César Milstein and Georges Kohler - scientists at the Roche-funded Basel Institute for Immunology - who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological researc......
  • China Antibody Market Research Report 2018
    Published: 23-Feb-2018        Price: US 3400 Onwards        Pages: 102
    The global Antibody market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. China plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of xx%. This report studies the Antibody development status and future trend in China, focuses on top players in China, also splits Antibody by type and by appl......
  • Global Antibody Market Professional Survey Report 2018
    Published: 16-Feb-2018        Price: US 3500 Onwards        Pages: 107
    This report studies Antibody in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Hytest - Roche - Thermo Fisher - Fapon - Genscript - Kitgen......
  • Anti GM-CSF Antibody - Pipeline Insight
    Published: 31-Jan-2018        Price: US 1250 Onwards        Pages: 60
    "Anti GM-CSF Antibody - Pipeline Insight, 2018" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Anti GM-CSF Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pip......
  • Anti-CD152 Antibody - Pipeline Insight
    Published: 31-Jan-2018        Price: US 1250 Onwards        Pages: 60
    "Anti-CD152 Antibody - Pipeline Insight, 2018" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Anti-CD152 Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipel......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs